loading
Pliant Therapeutics Inc stock is traded at $1.45, with a volume of 619.41K. It is up +0.00% in the last 24 hours and down -7.64% over the past month. Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$1.45
Open:
$1.44
24h Volume:
619.41K
Relative Volume:
0.50
Market Cap:
$89.01M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.4693
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
-6.45%
1M Performance:
-7.64%
6M Performance:
-52.92%
1Y Performance:
-89.02%
1-Day Range:
Value
$1.435
$1.49
1-Week Range:
Value
$1.395
$1.6089
52-Week Range:
Value
$1.1001
$16.10

Pliant Therapeutics Inc Stock (PLRX) Company Profile

Name
Name
Pliant Therapeutics Inc
Name
Phone
650-481-6770
Name
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Name
Employee
171
Name
Twitter
Name
Next Earnings Date
2024-11-07
Name
Latest SEC Filings
Name
PLRX's Discussions on Twitter

Compare PLRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
PLRX
Pliant Therapeutics Inc
1.45 96.38M 5.03M -185.41M -139.79M -3.09
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
395.12 99.96B 11.39B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
589.48 60.83B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
454.38 59.89B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
660.00 40.47B 3.06B 1.28B 447.35M 21.30
Biotechnology icon
ONC
Beone Medicines Ltd Adr
313.67 37.96B 3.81B -644.79M -669.77M -6.24

Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-04-25 Resumed Cantor Fitzgerald Neutral
Mar-04-25 Downgrade Needham Buy → Hold
Mar-03-25 Downgrade Leerink Partners Outperform → Market Perform
Mar-03-25 Downgrade Stifel Buy → Hold
Feb-10-25 Downgrade Canaccord Genuity Buy → Hold
Feb-10-25 Downgrade Citigroup Buy → Neutral
Feb-10-25 Downgrade H.C. Wainwright Buy → Neutral
Feb-10-25 Downgrade JP Morgan Overweight → Neutral
Feb-10-25 Downgrade Oppenheimer Outperform → Perform
Feb-10-25 Downgrade RBC Capital Mkts Outperform → Sector Perform
Feb-10-25 Downgrade Wells Fargo Overweight → Equal Weight
Sep-09-24 Resumed Leerink Partners Outperform
Dec-08-23 Initiated Wells Fargo Overweight
May-18-23 Initiated Canaccord Genuity Buy
Apr-13-23 Initiated Robert W. Baird Outperform
Dec-14-22 Initiated Stifel Buy
Dec-07-22 Initiated JP Morgan Overweight
Sep-01-22 Initiated Citigroup Buy
Jul-20-22 Initiated SVB Leerink Outperform
May-25-22 Initiated Cantor Fitzgerald Overweight
Dec-10-21 Initiated Oppenheimer Outperform
Nov-24-21 Initiated RBC Capital Mkts Outperform
Nov-03-21 Initiated H.C. Wainwright Buy
Apr-20-21 Initiated BTIG Research Buy
Apr-05-21 Initiated Citigroup Buy
Jun-29-20 Initiated Citigroup Buy
Jun-29-20 Initiated Cowen Outperform
Jun-29-20 Initiated Needham Buy
Jun-29-20 Initiated Piper Sandler Overweight
View All

Pliant Therapeutics Inc Stock (PLRX) Latest News

pulisher
Aug 17, 2025

Relative strength of Pliant Therapeutics Inc. in sector analysis2025 Macro Impact & Low Drawdown Investment Strategies - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Has Pliant Therapeutics Inc. formed a bullish divergence2025 EndofYear Setup & Proven Capital Preservation Methods - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Will Pliant Therapeutics Inc. stock split in the near futureExit Point & Momentum Based Trading Ideas - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Will Pliant Therapeutics Inc. price bounce be sustainableMarket Sentiment Review & Technical Entry and Exit Alerts - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Using Ichimoku Cloud for Pliant Therapeutics Inc. technicalsWeekly Trend Report & Free Growth Oriented Trading Recommendations - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

What recovery options are there for Pliant Therapeutics Inc.Bull Run & Low Drawdown Investment Ideas - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

What makes Pliant Therapeutics Inc. stock price move sharplyWeekly Trade Review & Free High Accuracy Swing Entry Alerts - Newser

Aug 17, 2025
pulisher
Aug 17, 2025

Backtesting results for Pliant Therapeutics Inc. trading strategiesGlobal Markets & AI Driven Price Predictions - Newser

Aug 17, 2025
pulisher
Aug 16, 2025

How to recover losses in Pliant Therapeutics Inc. stockJuly 2025 Levels & Smart Allocation Stock Tips - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Ranking Pliant Therapeutics Inc. among high performing stocks via toolsPortfolio Gains Report & Consistent Profit Trade Alerts - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Is now a turning point for Pliant Therapeutics Inc.July 2025 Chart Watch & High Accuracy Investment Entry Signals - Newser

Aug 16, 2025
pulisher
Aug 16, 2025

Will Pliant Therapeutics Inc. Sustain Its Chart BreakoutPortfolio Return Report & Weekly High Conviction Ideas - beatles.ru

Aug 16, 2025
pulisher
Aug 16, 2025

Using Bollinger Bands to evaluate Pliant Therapeutics Inc.CEO Change & Accurate Intraday Trade Tips - Newser

Aug 16, 2025
pulisher
Aug 15, 2025

Pliant Therapeutics Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingJuly 2025 Decliners & Breakout Confirmation Alerts - Newser

Aug 15, 2025
pulisher
Aug 15, 2025

Short Interest Drops in Pliant Therapeutics Inc. After Rally2025 Support & Resistance & Growth Focused Stock Reports - newsyoung.net

Aug 15, 2025
pulisher
Aug 15, 2025

Is Pliant Therapeutics Inc. currently under institutional pressureJuly 2025 Sector Moves & Verified Momentum Stock Ideas - metrotimes.co.kr

Aug 15, 2025
pulisher
Aug 14, 2025

Pliant Therapeutics Reports Q2 2025 Financial Results - TipRanks

Aug 14, 2025
pulisher
Aug 13, 2025

Is Pliant Therapeutics Inc. a defensive stockMarket Volume Summary & Free High Accuracy Swing Entry Alerts - thegnnews.com

Aug 13, 2025
pulisher
Aug 11, 2025

Citi Maintains Pliant Therapeutics(PLRX.US) With Hold Rating, Maintains Target Price $1.7 - 富途牛牛

Aug 11, 2025
pulisher
Aug 11, 2025

How to manage a losing position in Pliant Therapeutics Inc.High Return Trade Roadmap with Setup Filters - Newser

Aug 11, 2025
pulisher
Aug 10, 2025

Citi Raises Pliant Therapeutics Price Target to $1.70 Amid Unclear Path Forward - AInvest

Aug 10, 2025
pulisher
Aug 10, 2025

Healthcare Sector Analysts Weigh In on Sangamo Biosciences, Pliant Therapeutics, and Zimmer Biomet Holdings - AInvest

Aug 10, 2025
pulisher
Aug 09, 2025

Citi Reaffirms Their Hold Rating on Pliant Therapeutics (PLRX) - The Globe and Mail

Aug 09, 2025
pulisher
Aug 09, 2025

A Quick Look at Today's Ratings for Pliant Therapeutics(PLRX.US), With a Forecast Between $1.7 to $4 - 富途牛牛

Aug 09, 2025
pulisher
Aug 08, 2025

Pliant Therapeutics Pivots To Oncology After Ending IPF Program - Finimize

Aug 08, 2025
pulisher
Aug 08, 2025

Pliant Therapeutics shares fall 1.25% intraday after workforce realignment and BEACON-IPF closure. - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

RBC Capital Maintains Pliant Therapeutics(PLRX.US) With Hold Rating, Maintains Target Price $3 - 富途牛牛

Aug 08, 2025
pulisher
Aug 08, 2025

Pliant Therapeutics stock price target slashed by Piper Sandler - Investing.com Canada

Aug 08, 2025
pulisher
Aug 08, 2025

Needham Maintains Pliant Therapeutics(PLRX.US) With Hold Rating - 富途牛牛

Aug 08, 2025
pulisher
Aug 08, 2025

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results - 富途牛牛

Aug 08, 2025
pulisher
Aug 08, 2025

Pliant Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 08, 2025
pulisher
Aug 07, 2025

Pliant Therapeutics reports Q2 EPS (71c), consensus (68c) - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Pliant Therapeutics Q2 net loss narrows - MarketScreener

Aug 07, 2025
pulisher
Aug 07, 2025

Pliant Therapeutics reports Q2 FY25 financial results, Phase 1 oncology trial on track. - AInvest

Aug 07, 2025
pulisher
Aug 05, 2025

Pliant Therapeutics shares rise 2.65% intraday after IDEAYA Biosciences reports positive Phase 2/3 trial data. - AInvest

Aug 05, 2025
pulisher
Aug 04, 2025

Should I hold or sell Pliant Therapeutics Inc. stock in 2025Tremendous financial leverage - Jammu Links News

Aug 04, 2025
pulisher
Aug 03, 2025

Pliant Therapeutics Inc. Stock Analysis and ForecastRapidly expanding wealth - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How many analysts rate Pliant Therapeutics Inc. as a “Buy”Identify undervalued stocks ready to soar - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

A Quick Look at Today's Ratings for Pliant Therapeutics(PLRX.US), With a Forecast Between $3 to $17 - 富途牛牛

Aug 03, 2025
pulisher
Aug 03, 2025

How volatile is Pliant Therapeutics Inc. stock compared to the marketDiscover hidden gems in the stock market - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

How does Pliant Therapeutics Inc. compare to its industry peersInvest confidently with market-leading analysis - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Is Pliant Therapeutics Inc. a good long term investmentInvest confidently with expert support - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

Does Pliant Therapeutics Inc. stock perform well during market downturnsAchieve rapid portfolio growth with expert guidance - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What is the risk reward ratio of investing in Pliant Therapeutics Inc. stockGame-changing returns - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

What are Pliant Therapeutics Inc. company’s key revenue driversDiscover undervalued opportunities early - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

What is Pliant Therapeutics Inc. company’s growth strategyBuild wealth steadily with smart stock selection - Jammu Links News

Aug 02, 2025
pulisher
Aug 01, 2025

Pliant Therapeutics Inc. Trading Near Value Zone — Recovery AheadTop Performing Stock Insights Released Daily - metal.it

Aug 01, 2025

Pliant Therapeutics Inc Stock (PLRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Pliant Therapeutics Inc Stock (PLRX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Cummings Keith Lamont
Chief Financial Officer
Jan 17 '25
Sale
11.20
20,148
225,680
262,608
Hull Hans
Chief Business Officer
Jan 17 '25
Sale
11.20
15,936
178,501
211,558
Lefebvre Eric
Chief Medical Officer
Jan 17 '25
Sale
11.20
18,478
206,974
194,574
Cheung Lily
Chief Human Resource Officer
Jan 17 '25
Sale
11.20
3,740
41,892
24,550
Ouimette Mike
General Counsel & Corp. Sec'y
Jan 17 '25
Sale
11.20
13,270
148,639
80,774
Ouimette Mike
General Counsel & Corp. Sec'y
Jan 22 '25
Sale
10.99
10,230
112,462
70,544
$24.65
price up icon 0.94%
$85.04
price down icon 1.72%
$26.20
price up icon 0.73%
$110.88
price up icon 0.10%
$131.88
price down icon 0.54%
biotechnology ONC
$313.67
price down icon 0.10%
Cap:     |  Volume (24h):